Background Aging brains exhibit a shift from NMDA‑receptor‑dependent, input‑specific long‑term potentiation (LTP) to L‑type calcium channel (LTCC)‑driven, calcium‑induced calcium release (CICR)–mediated plasticity that is non‑selective and promotes over‑consolidation of memory traces [1]. This functional rigidity correlates more strongly with cognitive decline than structural loss such as dendritic spine reduction or neurogenesis decline [1,2]. Notably, structural damage persists even when function improves through interventions like exercise or cognitive training [4], indicating that plasticity mechanisms are a reversible lever.

Hypothesis We propose that intermittent, low‑dose pharmacological blockade of neuronal LTCCs (e.g., using isradipine) paired with periodic exposure to high‑novelty environments will selectively suppress pathological LTCC/CICR‑dependent LTP while permitting NMDA‑receptor‑dependent, input‑specific LTP to re‑emerge. The novelty component will transiently elevate dopaminergic tone in the hippocampus, which phosphorylates LTCC subunits via PKA/PKC pathways, reducing their open probability and further biasing calcium signaling toward NMDA receptors [3]. Together, this combination should reset the cost‑benefit balance of synaptic updating, reducing maladaptive over‑consolidation without requiring repair of lost spines or neurons.

Mechanistic Rationale

1. LTCC blockade diminishes global calcium spikes that trigger heterosynaptic, non‑input‑specific LTP, thereby limiting the “over‑writing” of synapses.
2. Novelty‑induced dopamine activates D1/D5 receptors, increasing cAMP/PKA activity that phosphorylates LTCCs (especially Cav1.2) to decrease their conductance and simultaneously enhances NMDA receptor trafficking to the synapse.
3. The alternating low‑dose drug schedule prevents compensatory upregulation of LTCC expression, while novelty bouts provide timed windows where NMDA‑dependent plasticity can be expressed behaviorally.
4. Because structural spine loss continues, any functional improvement will be detectable as a change in the quality of plasticity (e.g., restoration of NMDA‑dependent LTP magnitude and input specificity) rather than a rescue of spine number.

Predictions

• Aged mice receiving the combined treatment will show (a) restored NMDA‑dependent LTP in hippocampal slices, measured as increased input‑specificity (paired‑pulse facilitation unchanged, LTP blocked by APV but not by nifedipine) and (b) reduced LTCC/CICR‑dependent LTP (resistant to APV, sensitive to nifedipine) compared with age‑matched controls.
• Behaviorally, treated animals will improve on pattern separation tasks (e.g., object location discrimination) without significant changes in overall locomotor activity or anxiety.
• Longitudinal two‑photon imaging will reveal that spine turnover rates remain low (reflecting ongoing structural loss), but the fraction of spines exhibiting stable, NMDA‑dependent calcium transients during learning will increase.
• If either LTCC blockade or novelty exposure is administered alone, the rescue of NMDA‑dependent LTP and behavioral improvement will be significantly attenuated or absent.

Experimental Design

• Subjects: 20‑month‑old C57BL/6J mice (n=12 per group).
• Groups: (1) Vehicle + standard housing, (2) LTCC antagonist low dose (isradipine 5 mg/kg, i.p., 3×/week), (3) Novelty exposure (rotating novel objects in home cage, 2 h/day, 3×/week), (4) Combined LTCC antagonist + novelty.
• Outcome Measures: After 4 weeks, acute hippocampal slice electrophysiology (LTP assays with APV/nifedipine), in vivo calcium imaging during learning, and behavioral testing (pattern separation, Morris water maze reversal).
• Analysis: Two‑way ANOVA (drug × novelty) with post‑hoc tests; significance set at p<0.05.

Falsifiability If the combined treatment fails to produce a statistically significant increase in NMDA‑dependent LTP magnitude or input specificity, and does not improve pattern separation performance relative to either monotherapy or controls, the hypothesis is falsified. Conversely, a selective restoration of NMDA‑dependent plasticity coupled with behavioral benefit, despite unchanged spine numbers, would support the claim that age‑related cognitive rigidity can be pharmacologically and experientially reset without reversing underlying structural decay.